Quantitative PCR
From standard curves like the one shown in Figure S1 , each C 1/2 value of the tissue samples is converted into an aptamer concentration using the slope and intercept determined from linear regression. These concentrations are then converted into molecules (using Avogadro's number and the mass of the bare aptamer). Finally, each concentration was divided by 5 mg of tissue (the amount used to seed the qPCR reaction) to arrive at a normalized concentration value. Grubbs test was then performed to determine if any of the 3-7 values represented an outlier, which was removed from the data. The final normalized concentrations (molecules/mg tissue) for each mouse for each tissue at each time point are given in Tables S1-S5 . It should be emphasized that at most two digits are significant in the tables that follow, but integer concentrations are shown to allow for computation of means and standard deviations. The mean (and standard deviation) values were used to construct Figures 2-4 of the main text and for pharmacokinetic modeling. Spleen  1212328685  892283924 2229615531  483437053  399201  36087  2199327699 2237994690 2281263647  564122240 19853732  70014  4206610455 3762435933 3527974975 1729108497 21812908  362566  5401333247 4507666819 6709622832 2310706313 69198017  1312337  8173240404  Kidney  401171766  43307015  2709840  5015137  1084995  1870  527015476  75934220  9694939  8194079  1128906  31865  1198596615  80755742  46101564  9485021  89004  1818182076  104723782  94702740  Blood  2184375  192505002  65966831  5145631  316291  27584  28660172  352268556  65970900  9534839  711058  33055  71408720  836840590 
Pharmacokinetic modeling
The gamma variate function
Consider a probability density function of the form
where α and β are parameters describing the function and Γ(n) is the gamma function given by
This density function is equivalent to a concentration-time curve, C(t), in which each time point is divided by the total area under the concentration-time curve, A(∞), thus transforming each input into a probability measure. Making the substitution
the concentration-time curve becomes
The area under this concentration-time curve (up to time T ) is
and with the substitutions t = βx, dt = βdx, and α = n − 1 it follows that
where γ(n, T ) is the lower incomplete gamma function
which is equal to the product of the gamma function and the gamma distribution function P (n, T ) given by
As T → ∞, it follows that γ(n, T ) → Γ(n) and the equivalence between Equation S6 at infinite T and Equation S3 becomes clear. Because integration of C(t) (from 0 to ∞) produces a gamma function, this concentration function is known as a gamma variate.
To facilitate interpretation of the parameters α, β, and γ, we rearrange the gamma variate function as follows. First, we make the substitution
The parameter k has units of concentration (and is related to concentration maximum), β has units of time, and α is dimensionless. Next, we make the substitutions α = ln 2/a and β = b/ ln 2 so that C(t) has final form
In this form, the parameter b represents an effective half-life. Finally, we make substitutions in Equation S6, resulting in the following final form of A(T )
Sum of two gamma variates
Shown in Figure S2 , the experimental data sets are modeled as the sum of two gamma variates Figure S2 : Schematic illustration of pharmacokinetic data modeled as the sum of two gamma variates. An example fitting curve expresses recovered aptamer concentration (molecules per mg extracted tissue) on a logarithmic scale as a function of time (in hours) after i.p. injection. Data are well fit by the sum (gray) of two gamma variates (red and blue) describing an initial rapid aptamer accumulation and partial depletion phase, followed by a slow first-order exponential decay phase. 
C(t)
where M is the number of time points being fit, t m are times in minutes (corresponding to the m-th time point),C m are experimentally determined mean concentrations, σC m are standard deviations ofC m , and C(t m ; p) are theoretical predictions of the model. Optimizations were performed using a simplex and inductive search hybrid algorithm (SIH).
Monte Carlo estimation of uncertainty
Simulated data sets were generated from the experimental data by adding Gaussian noise, i.e. randomly sampling from the normal distributions N m (µ =C m , σ = σC m ). These simulated data sets (N m for = 1, . . . , max ) were fitted with the pharmacokinetic model to determine p min
For a given parameter p k , the median was taken and the standard deviation was estimated as
where max was set at 10,000 andp k is the mean valuē
Additionally, the relative bias in the parameter p k is given by
The median relative bias of all parameter estimates was ∼3 percent, giving confidence in the method.
Parameters from concentration-time curves Figure S3 : Parameters from fitting concentration data with pharmacokinetic model. Values of k 1 , k 2 , a 1 , a 2 , b 1 , and b 2 determined from fitting are given in Two additional parameters of interest are time to peak (t p )
and peak concentration (C p ) achieved at t p
Since the pharmacokinetic model is a sum of two gamma variates, the observed t p occurs near but not precisely at t p1 . Likewise, the observed C p reflects the sum of C p1 plus the value of C 2 evaluated at the observed t p . However, as shown in Table S6 , in most cases this contribution is negligible as t p ≈ t p1 and C p ≈ C p1 . 
